Echinocandins in the management of invasive fungal infections, part 2

Morris, Michele; Villmann, Mark

doi:10.2146/ajhp050464.p2

Cited by 44 publications

(31 citation statements)

References 60 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fungal bloodstream infections are common ICU infections that are associated with high mortality rates [54]. In the retrospective cohort analysis of patients with Candida bloodstream infection (described above), initial empirical therapy was achieved for only 9 of 157 patients within 12 h of collection of the first blood sample for positive culture and was shown to be important in reducing the risk of in-hospital mortality [31].…”

Section: Bloodstream Infectionsmentioning

confidence: 99%

See 1 more Smart Citation

Broad‐Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front

2008

View full text Add to dashboard Cite

The treatment of serious bacterial infections is complicated by the fact that time to initiation of effective antimicrobial therapy is a strong predictor of mortality. Therefore, therapy must be initiated before the causative pathogen is identified. However, inappropriate or inadequate initial empirical therapy is associated with increased mortality, morbidity, and length of hospital stay. Initial empirical therapy with broad-spectrum antimicrobials attempts to address this dilemma by "getting it right up front." The goal is to provide treatment active against the most likely pathogens until culture/susceptibility test results are obtained. After the causative pathogen is identified, streamlining to more-precise therapy of the shortest acceptable duration is implemented. In this way, the risks of death, morbid complications, increased duration of hospital stay (as a result of ineffective initial treatment), and emergence of resistance (due to extended treatment with broad-spectrum agents) are lowered. Improved clinical and economic outcomes after such an approach have been demonstrated.

show abstract

Section: Bloodstream Infectionsmentioning

confidence: 99%

“…against organisms that are resistant to these agents [56]. Newer antifungal agents that have become available recently are the echinocandins (caspofungin, micafungin, and anidulafungin), which have fungicidal activity against yeast and fungistatic activity against mold [54].…”

Section: Bloodstream Infectionsmentioning

confidence: 99%

Broad‐Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front

2008

View full text Add to dashboard Cite

show abstract

“…However, MCF seems effective in hematopoietic stem cell transplant recipients and the treatment of esophageal candidiasis. ANF received approved labeling from the Food and Drug Administration in February 2006 [21].…”

Section: Echinocandins: the Potential Source As An Antifungal Agentmentioning

confidence: 99%

Echinocandins Versus Dated Antifungals in Combination Against Opportunistic Mycotic Infections

Narwal¹,

Balhara²,

Chaudhary³

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Scientific and clinical reports globally demonstrated that the opportunistic mycotic infections are at major risk to the human fitness. In the past few decades, the development of resistance in microbes to existing antifungals has emphasized on the search of new antimycotic drugs. As a matter of fact, "echinocandins" are new categories of broad-spectrum antifungal enlighten a hope in this direction. Echinocandins are bulky lipopeptides that inhibit the production of β-[1,3]-glucan "a major constituent of fungal cell wall" which ultimately leads to the death of fungal pathogens. In vitro as well as in vivo published reports have demonstrated that the echinocandins exhibit fungicidal activity against most Candida spp., while fungistatic against Aspergillus spp. and exclusively found to be more effective when tested in combination with polyenes/azoles. The present article is expert views on the recent and historical literature available on the antifungal therapies with accessing their impact on the human health. Emphasis is given to the utility of the echinocandins a potental antifungal agent by discussing recent examples of clinical and laboratory studies including the use of improved proteomics approaches to know a bit more about the interaction of human host and fungal pathogens.

show abstract

“…Echinocandins are semisynthetic lipopeptides that inhibit the synthesis of glucan in the fungal cell wall through non-competitive inhibition of the enzyme 1,3-â-glucan synthase, causing osmotic imbalance and cell lysis (8,119,120) . This class of drugs includes caspofungin (CFG) and micafungin (MFG).…”

Section: Echinocandinsmentioning

confidence: 99%

Antifúngicos em infecções oculares: drogas e vias de administração

Müller¹,

Kara‐José²,

Castro³

2013

Rev. bras.oftalmol.

View full text Add to dashboard Cite

RESUMOO tratamento das infecções oculares por fungos representa um desafio à prática oftalmológica. Para obtermos resposta terapêutica adequada, além do uso da droga correta, é necessária a administração desta de forma eficaz. Este manuscrito reúne informações a respeito das principais drogas antifúngicas utilizadas em infecções oculares, suas concentrações e principais vias de administração.

show abstract

Echinocandins in the management of invasive fungal infections, part 2

Cited by 44 publications

References 60 publications

Broad‐Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front

Broad‐Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front

Echinocandins Versus Dated Antifungals in Combination Against Opportunistic Mycotic Infections

Antifúngicos em infecções oculares: drogas e vias de administração

Contact Info

Product

Resources

About